Compare Hudbay Minerals Inc. Ordinary Shares (Canada) (HBM) vs Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hudbay Minerals Inc. Ordinary Shares (Canada) vs Maravai LifeSciences Holdings Inc. Class A Common Stock — how do they compare? Hudbay Minerals Inc. Ordinary Shares (Canada) trades at $23.91 (market cap $11.37B), while Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $972.90M). The key difference: Hudbay Minerals Inc. Ordinary Shares (Canada) is far larger — about 11.7× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and Hudbay Minerals Inc. Ordinary Shares (Canada) pays a 0.11% dividend while Maravai LifeSciences Holdings Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Hudbay Minerals Inc. Ordinary Shares (Canada) for 6 Days and Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days on average.
| HBM | MRVI | |
|---|---|---|
Market Cap | $11.37B | $972.90M |
Volume | 3,520,423 | 4,325,710 |
Sector | Basic Materials | Health |
52-Week High | $31.87 | $9.00 |
52-Week Low | $14.58 | $2.83 |
Typical Hold Time | 6 Days | 0 Days |
Enterprise Value | $11.43B | $1.08B |
Dividend Yield | 0.11% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HudBay Minerals (HBM) trades at $25.68, down 0.31% with bearish technical signals despite solid fundamentals. The company reported strong 2025 results with $2.21B revenue and $568.5M net income, while analyst consensus remains positive with 60% buy ratings. Recent news highlights HBM4 equipment delays and copper/gold reserve expansions at Snow Lake operations.
HBM presents a value opportunity with reasonable valuation (P/E 15.77) and strong profitability (ROE 18.43%), though technical weakness and HBM market dynamics pose near-term risks. The stock's outlook depends on execution of copper growth strategy and resolution of memory sector supply chain concerns.
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Hudbay Minerals Inc. Ordinary Shares (Canada)
Hudbay Minerals is a mining company producing copper, gold, zinc, and other metals. Its operations are located in the Americas.
Read more on HBM →About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →
